Acadia Pharmaceuticals (ACAD) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
2 figures withheld by our checks. Each blank figure names its reason.
160.5mn → 169.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲797% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
36¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 96.0% → 91.7%. Net margin 36.5% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,202,301.0 | 1,071,505.0 | 957,797.0 | 726,437.0 | 517,235.0 | 484,145.0 | ▲11.9% | +22.0% |
Cost of revenue | 114,422.0 | 88,998.0 | 81,841.0 | 41,638.0 | 10,166.0 | 19,141.0 | ▲8.7% | +46.8% |
Gross profit | 1,087,879.0 | 982,507.0 | 875,956.0 | 684,799.0 | —A | 465,004.0 | ▲12.2% | — |
Research & development | 319,462.0 | 328,802.0 | 303,249.0 | 351,619.0 | 361,575.0 | 239,415.0 | ▲8.4% | +8.3% |
Selling, general & admin | 646,088.0 | 548,894.0 | 488,428.0 | 406,559.0 | 369,090.0 | 396,028.0 | ▲12.4% | +8.5% |
Total operating expenses | 965,550.0 | 877,696.0 | 645,162.0 | 758,178.0 | 730,665.0 | 635,443.0 | ▲36.0% | +8.4% |
Operating incomefeeds ROC rank | 122,329.0 | 104,811.0 | 230,794.0 | −73,379.0 | −223,596.0 | −170,439.0 | ▼54.6% | — |
Other income, net | 34,883.0 | 34,093.0 | 27,281.0 | 22,343.0 | 10,152.0 | 2,920.0 | — | — |
Pretax income | 157,212.0 | 138,904.0 | 258,075.0 | −51,036.0 | −213,444.0 | −167,519.0 | ▼46.2% | — |
Income tax | −205,017.0 | −252,096.0 | 31,624.0 | 10,250.0 | 2,531.0 | 351.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 362,229.0 | 391,000.0 | 226,451.0 | −61,286.0 | −215,975.0 | −167,870.0 | ▲72.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.12 | 2.30 | 1.36 | −0.37 | −1.34 | −1.05 | ▲69.1% | — |
Diluted shares (mn) | 175.47 | 169.92 | 166.36 | 163.82 | 161.68 | 160.49 | ▲2.1% | +1.4% |
| Margins | ||||||||
Gross margin86th pct in Healthcare | 90.5% | 91.7% | 91.5% | 94.3% | —A | 96.0% | ▲0.2pp | — |
Operating margin | 10.2% | 9.8% | 24.1% | −10.1% | −43.2% | −35.2% | ▼14.3pp | +45.0pp |
Net margin95th pct in Healthcare | 30.1% | 36.5% | 23.6% | −8.4% | −41.8% | −34.7% | ▲12.8pp | +71.2pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Acadia Pharmaceuticals' revenue last fiscal year?
Acadia Pharmaceuticals reported revenue of $1,071.5M in fiscal 2025, up 11.9% from fiscal 2024.
What was Acadia Pharmaceuticals' net income?
Acadia Pharmaceuticals reported net income of $391.0M in fiscal 2025, a net margin of 36.5%.

